exactly, especially when Gilead pays $21 billion for trodelvy alone and when GSK already spent $5.1 billion for dolstarlimab alone.

This CCR5 binder/blocker does everything those do and 50x more. CCR5 blockade makes Leronlimab the perfect molecule to pair with, especially since Leronlimab has no black box warnings and no ASE.